Terms: = Skin cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717
103 results:
1. The role of thymic stromal lymphopoietin in cutaneous disorders.
Jafari AJ; Rivera M; Hebert AA
Arch Dermatol Res; 2024 Apr; 316(5):123. PubMed ID: 38630260
[TBL] [Abstract] [Full Text] [Related]
2. Lymphadenectomy After Melanoma-A National Analysis of Recurrence Rates and Risk of Lymphedema.
Shen C; Shah JK; Cevallos P; Nazerali R; Rosen JM
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S284-S292. PubMed ID: 38556691
[TBL] [Abstract] [Full Text] [Related]
3. Effects of extracellular vesicles from adipose-derived stem cells on human keloid fibroblasts via the SOCS1/jak2/STAT3 pathway.
Ruan H; Wang J; Shi H; Luan W
J Cosmet Dermatol; 2024 Apr; 23(4):1404-1416. PubMed ID: 38288516
[TBL] [Abstract] [Full Text] [Related]
4. Radix Tetrastigma Hemsleyani Flavone represses cutaneous squamous cell carcinoma via Janus kinase/signal transducer and activator of transcription 3 pathway inactivation.
Peng J; Luo X; Wang T; Yue C; Duan M; Wu C
Cytokine; 2024 Mar; 175():156480. PubMed ID: 38232644
[TBL] [Abstract] [Full Text] [Related]
5. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract] [Full Text] [Related]
6. Associations of A20, CYLD, Cezanne and jak2 Genes and Immunophenotype with Psoriasis Susceptibility.
Giang NH; Lien NTK; Trang DT; Huong PT; Hoang NH; Xuan NT
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893484
[No Abstract] [Full Text] [Related]
7. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
[TBL] [Abstract] [Full Text] [Related]
8. Acute graft-versus-host disease.
Malard F; Holler E; Sandmaier BM; Huang H; Mohty M
Nat Rev Dis Primers; 2023 Jun; 9(1):27. PubMed ID: 37291149
[TBL] [Abstract] [Full Text] [Related]
9. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract] [Full Text] [Related]
10. MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of jak2.
Markovits E; Harush O; Baruch EN; Shulman ED; Debby A; Itzhaki O; Anafi L; Danilevsky A; Shomron N; Ben-Betzalel G; Asher N; Shapira-Frommer R; Schachter J; Barshack I; Geiger T; Elkon R; Besser MJ; Markel G
Cancer Immunol Res; 2023 Jul; 11(7):909-924. PubMed ID: 37074069
[TBL] [Abstract] [Full Text] [Related]
11. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
[TBL] [Abstract] [Full Text] [Related]
12. CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma.
Nishida H; Kondo Y; Kusaba T; Kawamura K; Oyama Y; Daa T
PLoS One; 2023; 18(2):e0281647. PubMed ID: 36780540
[TBL] [Abstract] [Full Text] [Related]
13. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract] [Full Text] [Related]
14. Dioscin induces M1 macrophage polarization through Connexin-43 Channels in Tumor-associated-macrophages-mediated melanoma metastasis.
Kou Y; Sun Q; Zhu R; Lin Z; Li Z; Xu H; Feng X; Liu Y
Phytomedicine; 2023 Jan; 109():154559. PubMed ID: 36610151
[TBL] [Abstract] [Full Text] [Related]
15. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T; Katoh N; Simpson EL; de Bruin-Weller M; Thaçi D; Torrelo A; Sontag A; Grond S; Issa M; Lu X; Cardillo T; Holzwarth K; Thyssen JP
J Dermatolog Treat; 2023 Dec; 34(1):2161812. PubMed ID: 36546346
[TBL] [Abstract] [Full Text] [Related]
16. Therapeutic targets and signaling mechanisms of dasatinib activity against radiation skin ulcer.
Su W; Chen X; Zhang W; Li D; Chen X; Yu D
Front Public Health; 2022; 10():1031038. PubMed ID: 36530656
[TBL] [Abstract] [Full Text] [Related]
17. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract] [Full Text] [Related]
18. A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant.
Davies A; Salisbury J; Mehra V; Papa S; Basu T
Clin Exp Dermatol; 2022 Nov; 47(11):2059-2064. PubMed ID: 36004622
[TBL] [Abstract] [Full Text] [Related]
19. PCM1::jak2 fusion associates with an atypical form of mycosis fungoides.
Rodriguez-Sevilla JJ; Salido M; Rodriguez-Rivera M; Sanchez-Gonzalez B; Gallardo F; Pujol RM; Colomo L
Virchows Arch; 2022 Dec; 481(6):967-973. PubMed ID: 35786767
[TBL] [Abstract] [Full Text] [Related]
20. Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling.
Nédélec A; Guérit EM; Dachy G; Lenglez S; Wong LS; Arts FA; Demoulin JB
J Cell Mol Med; 2022 Jul; 26(14):3902-3912. PubMed ID: 35689379
[TBL] [Abstract] [Full Text] [Related]
[Next]
